Literature DB >> 25972949

Malignant fibrous histiocytoma of the skull base: A neurosurgical nuance.

Amit Mahore1, Raghvendra Ramdasi1, Nitin Dange1, Sridhar Epari2.   

Abstract

A 69-year-old male, treated for colonic carcinoma 15 years back, presented to our services with status epilepticus. He had complaints of headache and vomiting for 7 days prior to presentation. Computed tomography and magnetic resonance imaging of the brain revealed heterogeneous, lobulated and osteolytic tumor involving middle and posterior cranial fossa. Excision of the tumor was planned in two stages. Middle fossa component was removed through right temporobasal approach. Histopathology was suggestive of malignant fibrous histiocytoma. Patient succumbed to pneumonia and septicemia in the postoperative period. Pathology, clinical features and therapeutic challenges of this clinical entity have been briefly reviewed.

Entities:  

Keywords:  Skull base; calvarial sarcoma; malignant fibrous histiocytoma; metastasis; undifferentiated pleomorphic soft tissue sarcoma

Year:  2015        PMID: 25972949      PMCID: PMC4421955          DOI: 10.4103/1793-5482.154981

Source DB:  PubMed          Journal:  Asian J Neurosurg


Introduction

Undifferentiated pleomorphic sarcoma is a new terminology for malignant fibrous histiocytoma (MFH). Its occurrence in head and neck is rare.[123] We report a case of undifferentiated pleomorphic sarcoma of the skull base with the intradural extension.

Case Report

A 69-year-old male, who underwent surgery and chemotherapy for carcinoma of descending colon 15 years ago, was brought to our emergency department with status epilepticus. He had complaints of headache and vomiting for 7 days prior to presentation. The computed tomography scan of the brain showed an extensive osteolytic lesion of base of the skull in the right middle and posterior cranial fossa. It showed scattered calcification and mass effect on the brainstem [Figure 1a]. On magnetic resonance imaging, it showed an intense enhancement of contrast and encasement of carotid artery [Figure 1b–d]. A provisional diagnosis of metastasis from carcinoma of the colon was considered. Excision of the tumor was planned in two stages. He was subjected to right temporobasal craniotomy for removal of the middle fossa component at initial stage. In the second stage, an excision of the posterior fossa extension was planned. Tumor was firm and highly vascular with foci of calcification. It was originating from the base of the skull and had destroyed basal and petrous parts of the temporal bone. It had infiltrated into the temporal dura and brain. The base of the skull was repaired using temporalis muscle, fat, and fascia lata. Unfortunately, the patient developed pneumonitis and septicemia in the postoperative period and expired after 2 days. On histopathological examination, tumor was composed of sheets of large pleomorphic cells with marked nuclear pleomorphism and frequent mitoses. The tumor cells were positive for vimentin and negative for S-100 protein, smooth muscle actin, epithelial membrane antigen, and CD34. Histopathology was suggestive of undifferentiated pleomorphic sarcoma [Figure 2a–h].
Figure 1

(a) Postcontrast computed tomography of the brain showing heterogeneous, lobulated and osteolytic lesion in the right middle and posterior cranial fossa with scattered calcification and mass effect on brainstem. (b) postcontrast sagittal image, (c) plain axial image and (d) (postcontrast Axial image)-magnetic resonance imaging brain showing intense contrast enhancement, encasement of carotid artery, extension into infratemporal fossa and mass effect on brainstem by the lesion

Figure 2

Photomicrograph showing a malignant tumor within the bone (a) (H and E, ×25) composed of sheets of large pleomorphic cells with marked nuclear pleomorphism and frequent mitoses (b and c) (H and E, ×200; arrow for tumor giant cells and arrow head for mitoses). The tumor cells are positive for vimentin (d) (immunohistochemistry [IHC], ×200); while negative for S-100 protein (e) (IHC, ×200), smooth muscle actin (f) (IHC, ×200), epithelial membrane antigen (g) (IHC, ×200) and CD34 (h) (IHC, ×200)

(a) Postcontrast computed tomography of the brain showing heterogeneous, lobulated and osteolytic lesion in the right middle and posterior cranial fossa with scattered calcification and mass effect on brainstem. (b) postcontrast sagittal image, (c) plain axial image and (d) (postcontrast Axial image)-magnetic resonance imaging brain showing intense contrast enhancement, encasement of carotid artery, extension into infratemporal fossa and mass effect on brainstem by the lesion Photomicrograph showing a malignant tumor within the bone (a) (H and E, ×25) composed of sheets of large pleomorphic cells with marked nuclear pleomorphism and frequent mitoses (b and c) (H and E, ×200; arrow for tumor giant cells and arrow head for mitoses). The tumor cells are positive for vimentin (d) (immunohistochemistry [IHC], ×200); while negative for S-100 protein (e) (IHC, ×200), smooth muscle actin (f) (IHC, ×200), epithelial membrane antigen (g) (IHC, ×200) and CD34 (h) (IHC, ×200)

Discussion

Malignant fibrous histiocytoma is a synonym for the undifferentiated pleomorphic sarcoma as per the recent World Health Organization classification.[1] These are commonly found in the extremities (68%) and in the retro-peritoneum (16%). These tumors in the head region have rarely been reported.[23] The first report of the occurrence of MFH in central nervous system was given in 1976 by Gonzalez-Vitale et al.[4] The cranial MFH can have either extracranial or intracranial origin. Intracranially, these can arise from meninges, parenchyma or ventricle.[5] Extra-cranially these can arise from the scalp or the bone.[678] Bony origin can be either from the jaw bones or calvarium.[6] The calvarium is least common site of origin of MFH. Till date, only 15 such cases have been reported.[23469101112131415] The bones affected in the head region are temporal, parietal, fronto-temporal, occipito-temporal, fronto-parieto-temporal and clivus [Table 1].[4612] It is the first case of an extensive lesion occupying both middle and posterior cranial fossa and presenting with status epilepticus.
Table 1

Cases of malignant fibrous histocytoma arising from the bone

Cases of malignant fibrous histocytoma arising from the bone Malignant fibrous histiocytoma is known to occur in previously abnormal bone affected by radiation, infection, and trauma. It is also associated with Paget's disease and fibrous dysplasia.[16] MFH presents with varying degrees of bone destruction and mimics meningioma.[23] Radiologically MFH is seen as large lobulated mass with hypo to isointense regions and has heterogeneous enhancement on giving contrast. Hypointense regions are suggestive of necrosis, hemorrhage or myxomatous changes. Radiological differential diagnosis of MFH includes meningioma, osteosarcoma, chondrosarcoma, osteochondroma, dedifferentiated chordoma, plasmacytoma, lymphoma, and metastasis.[17] Malignant fibrous histiocytoma histologically consists of atypical fibroblasts and histiocytes in variable proportions. The diagnosis of MFH requires exclusion of other dedifferentiated pleomorphic sarcoma. It can be done by immunohistochemistry. It is vimentin positive and CD18 negative.[18] Four histological subtypes of MFH have been described. They are storiform-pleomorphic, myxoid, giant cell and inflammatory. The giant cell variant is associated with higher recurrence rate than storiform/pleomorphic MFH. It has a higher rate of metastasis than the inflammatory form.[19] There are various inherent problems involved in the management of MFH similar to the other malignancies of base of the skull. These are summarized below: The proximity to potentially infective spaces of paranasal sinuses Difficulty to achieve negative margins due to the presence of cranial nerve foramina, venous sinuses and major vessels of the brain in the vicinity Paucity of local tissues for transfers into the defect Need of multiple stages for surgical excision due to involvement of multiple compartments and Need of multiple blood transfusions due to rich vascularity. Treatment of MFH consists of radical excision, postoperative radiation, and chemotherapy. However, most of the patients die within 1-year of surgery. MFH has 5 years survival rate of 34–50%.[20] Lin et al. have published a retrospective clinical study of 28 cases of head and neck MFH. They have found a 3 years survival rate of 57.1%.[21] Our patient had status epilepticus due to invasion of temporal lobe by the tumor. The association between colonic cancer and MFH appears to be purely coincidental.

Conclusion

Pleomorphic undifferentiated sarcomas or MFHs arising from the skull base pose a therapeutic challenge to treating neurosurgeon. These should be considered in the differential diagnosis of aggressive, heterogeneous osteolytic lesions of the base of the skull.
  19 in total

1.  Malignant fibrous histiocytoma of scalp with intracranial invasion 20 years after postoperative irradiation.

Authors:  Junji Hayami; Ichiro Kurokawa; Kenji Hashimoto; Kenji Kusumoto
Journal:  J Craniofac Surg       Date:  2003-01       Impact factor: 1.046

2.  Radiation-induced intracranial malignant fibrous histiocytoma.

Authors:  J C Gonzalez-Vitale; R E Slavin; J D McQueen
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

3.  Malignant fibrous histiocytoma of the occipital bone with intracranial extension--case report.

Authors:  S Matsuura; T Takagi; E C Tan; S Mizuno; N Imagunbai; R Hasegawa
Journal:  Neurol Med Chir (Tokyo)       Date:  1991-04       Impact factor: 1.742

4.  [Clinical analysis on 28 cases of head-neck malignant fibrous histiocytoma].

Authors:  Xin Lin; Shaowen Zeng; Chu Yang; Chuangwei Li; Dongtao Yang
Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi       Date:  2009-10

5.  Malignant fibrous histiocytoma of the temporal bone with intracranial extension.

Authors:  V S Chitale; N Sundaresan; L Helson; A G Huvos
Journal:  Acta Neurochir (Wien)       Date:  1981       Impact factor: 2.216

6.  Malignant fibrous histiocytoma of bone. The experience at the Rizzoli Institute: report of 90 cases.

Authors:  R Capanna; F Bertoni; P Bacchini; G Bacci; A Guerra; M Campanacci
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

7.  Malignant fibrous histiocytoma originating at the site of a previous fronto-temporal craniotomy.

Authors:  Takashi Asahi; Masanori Kurimoto; Makoto Kawaguchi; Nobutaka Yamamoto; Syuji Sato; Shunro Endo
Journal:  J Clin Neurosci       Date:  2002-11       Impact factor: 1.961

8.  Malignant fibrous histiocytoma in the parietal bone.

Authors:  D Yoshida; K Harashima; Y Node; T Kojima; T Shimura; A Teramoto
Journal:  Neurol Med Chir (Tokyo)       Date:  1998-06       Impact factor: 1.742

9.  Malignant fibrous histiocytoma of the scalp: A rare differential with a dramatic clinical presentation.

Authors:  Arvind Krishnamurthy
Journal:  J Indian Assoc Pediatr Surg       Date:  2014-10

10.  Radiation-induced malignant fibrous histiocytoma of the occipital: a case report.

Authors:  Guo-Bin Zhang; Jian Li; Peng-Fei Zhang; Li-Jiang Han; Jun-Ting Zhang
Journal:  World J Surg Oncol       Date:  2014-04-17       Impact factor: 2.754

View more
  2 in total

1.  A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.

Authors:  Ning Zhou; Reinhold Schäfer; Tao Li; Meiyu Fang; Luying Liu
Journal:  BMC Cancer       Date:  2018-08-22       Impact factor: 4.430

2.  Intraventricular Undifferentiated Pleomorphic Sarcoma: A Case Report.

Authors:  Emily P Sieg; Hayk Stepanyan; Russell Payne; Elizabeth Frauenhoffer; Charles S Specht; Sara Langan; Elias Rizk
Journal:  Cureus       Date:  2016-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.